Survey on current practice within the European Low-Grade Glioma Network: Where do we stand and what is the next step?

Emmanuel Mandonnet, Michel Wager, Fabien Almairac, Marie-Helene Baron, Marie Blonski, Christian F. Freyschlag, Fabio Barone, Denys Fontaine, Johan Pallud, Monika Hegi, Catarina Viegas, Maria Zetterling, Giannantonio Spena, John Goodden, Geert-Jan Rutten, Luc Taillandier, Nicolas Foroglu, Amélie Darlix, Miran Skrap, Juan MartinoGord von Campe, Caterina Madadaki, Etienne Gayat, Philip de Witt Hamer, Santiago Gil Robles, Silvio Sarubbo, Thomas Santorius, Lorenzo Bello, Marie-Therese Forster, Hugues Duffau

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)


Diffuse low-grade glioma form a rare entity affecting young people. Despite advances in surgery, chemotherapy, and radiation therapy, diffuse low-grade glioma are still incurable. According to current guidelines, maximum safe resection, when feasible, is the first line of treatment. Apart from surgery, all other treatment modalities (temozolomide, procarbazine-CCNU-vincristine regimen, and radiation therapy) are handled very differently among different teams, and this in spite of recent results of several phase 3 studies. Based on a European survey, this paper aimed to get a picture of this heterogeneity in diffuse low-grade glioma management, to identify clinically relevant questions raised by this heterogeneity of practice, and to propose new methodological frameworks to address these questions.
Original languageEnglish
Pages (from-to)241-247
JournalNeuro-Oncology Practice
Issue number4
Publication statusPublished - 2017

Cite this